التفاصيل البيبلوغرافية
| العنوان: |
Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co( II) and Zn( II) compounds. |
| المؤلفون: |
Raposo, L. R., Roma‐Rodrigues, C., Jesus, J., Martins, L. M. D. R. S., Pombeiro, A. J., Baptista, P. V., Fernandes, A. R. |
| المصدر: |
Veterinary & Comparative Oncology; Dec2017, Vol. 15 Issue 4, p1537-1542, 1p |
| مصطلحات موضوعية: |
MAMMARY gland tumors, GOLD nanoparticles, CANCER in dogs, PHENANTHROLINE, NANOTECHNOLOGY, CISPLATIN, DOXORUBICIN |
| مستخلص: |
Background Despite continuous efforts, the treatment of canine cancer has still to deliver effective strategies. For example, traditional chemotherapy with doxorubicin and/or docetaxel does not significantly increase survival in dogs with canine mammary tumors (CMTs). Aims Evaluate the efficiency of two metal compounds [Zn(DION)2]Cl (TS262, DION = 1,10-phenanthroline-5,6-dione) and [CoCl(H2O)(DION)2][BF4] (TS265) and novel nanovectorizations designed to improve the anti-cancer efficacy of these compounds in a new CMT derived cell line (FR37-CMT). Materials and methods FR37-CMT cells were exposed to different concentrations of TS262 and TS265 and two new nanoparticle systems and cellular viability was determined. These nanosystems are composed of polyethylene-glycol, bovine-serum-albumin and TS262 or TS265 (NanoTS262 or NanoTS265, respectively). Results In FR37-CMT, TS262 and TS265 displayed IC50 values well below those displayed by doxorubicin and cisplatin. The nanovectorizations further decreased the IC50 values. Discussion TS262 and TS265 proved to be effective against FR37-CMT cells and more effective than of doxorubicin and cisplatin. The Nanosystems efficiently delivered the cytotoxic cargo inducing a significant reduction of cell viability in FR37-CMT cell line when compared to the free compounds. Conclusions TS262 and TS265 are compounds with potential in the treatment of CMTs. NanoTS262 and NanoTS265 demonstrate that such simple nanovectorization via gold nanoparticles shows tremendous potential as anti-cancer formulations, which may easily be expanded to suit other cargo. [ABSTRACT FROM AUTHOR] |
|
Copyright of Veterinary & Comparative Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |